These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20644562)

  • 1. Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease.
    Patterson CE; Todd SA; Passmore AP
    Pharmacogenomics J; 2011 Dec; 11(6):444-50. PubMed ID: 20644562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease.
    Lane R; Feldman HH; Meyer J; He Y; Ferris SH; Nordberg A; Darreh-Shori T; Soininen H; Pirttilä T; Farlow MR; Sfikas N; Ballard C; Greig NH
    Pharmacogenet Genomics; 2008 Apr; 18(4):289-98. PubMed ID: 18334913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.
    Bizzarro A; Marra C; Acciarri A; Valenza A; Tiziano FD; Brahe C; Masullo C
    Dement Geriatr Cogn Disord; 2005; 20(4):254-61. PubMed ID: 16103669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.
    De Beaumont L; Pelleieux S; Lamarre-Théroux L; Dea D; Poirier J;
    J Alzheimers Dis; 2016 Oct; 54(3):913-922. PubMed ID: 27567841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Most rapid cognitive decline in APOE epsilon4 negative Alzheimer's disease with early onset.
    van der Vlies AE; Koedam EL; Pijnenburg YA; Twisk JW; Scheltens P; van der Flier WM
    Psychol Med; 2009 Nov; 39(11):1907-11. PubMed ID: 19335933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients--an open-label trial.
    Kennelly S; Abdullah L; Kenny RA; Mathura V; Luis CA; Mouzon B; Crawford F; Mullan M; Lawlor B
    Int J Geriatr Psychiatry; 2012 Apr; 27(4):415-22. PubMed ID: 21560164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein ε4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease.
    Darreh-Shori T; Siawesh M; Mousavi M; Andreasen N; Nordberg A
    J Alzheimers Dis; 2012; 28(2):443-58. PubMed ID: 22012848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer's disease.
    Raygani AV; Zahrai M; Soltanzadeh A; Doosti M; Javadi E; Pourmotabbed T
    Neurosci Lett; 2004 Nov; 371(2-3):142-6. PubMed ID: 15519745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Butyrylcholinesterase-K Allele and Apolipoprotein E ɛ4 Allele with Cognitive Decline in Dementia with Lewy Bodies and Alzheimer's Disease.
    Vijayaraghavan S; Darreh-Shori T; Rongve A; Berge G; Sando SB; White LR; Auestad BH; Witoelar A; Andreassen OA; Ulstein ID; Aarsland D
    J Alzheimers Dis; 2016; 50(2):567-76. PubMed ID: 26757188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Butyrylcholinesterase K and apolipoprotein ε4 affect cortical thickness and neuropsychiatric symptoms in Alzheimer's disease.
    Yoo HB; Lee HW; Shin S; Park SW; Choi JS; Jung HY; Cha J; Lee JM; Lee JY
    Curr Alzheimer Res; 2014 Feb; 11(2):137-44. PubMed ID: 24479631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
    Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
    Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism.
    Darreh-Shori T; Brimijoin S; Kadir A; Almkvist O; Nordberg A
    Neurobiol Dis; 2006 Nov; 24(2):326-33. PubMed ID: 16973370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein epsilon4 and neuropsychological performance in Alzheimer's disease and vascular dementia.
    McGuinness B; Carson R; Barrett SL; Craig D; Passmore AP
    Neurosci Lett; 2010 Oct; 483(1):62-6. PubMed ID: 20678545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ApoE genotype on response to donepezil in patients with Alzheimer's disease.
    Choi SH; Kim SY; Na HR; Kim BK; Yang DW; Kwon JC; Park MY
    Dement Geriatr Cogn Disord; 2008; 25(5):445-50. PubMed ID: 18401173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of polymorphisms in the presenilin-1 gene and the butyrylcholinesterase gene as risk factors in sporadic Alzheimer's disease.
    Tilley L; Morgan K; Grainger J; Marsters P; Morgan L; Lowe J; Xuereb J; Wischik C; Harrington C; Kalsheker N
    Eur J Hum Genet; 1999 Sep; 7(6):659-63. PubMed ID: 10482954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein E genotypes in hospitalized elderly patients with vascular dementia.
    Orsitto G; Seripa D; Panza F; Franceschi M; Cascavilla L; Placentino G; Matera MG; Paris F; Capurso C; Solfrizzi V; Dallapiccola B; Pilotto A
    Dement Geriatr Cogn Disord; 2007; 23(5):327-33. PubMed ID: 17374951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Apolipoprotein E ɛ4 Carrier Status on Cognitive Response to Acetylcholinesterase Inhibitors in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis.
    Cheng YC; Huang YC; Liu HC
    Dement Geriatr Cogn Disord; 2018; 45(5-6):335-352. PubMed ID: 30041236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients.
    Han HJ; Kim BC; Lee JY; Ryu SH; Na HR; Yoon SJ; Park HY; Shin JH; Cho SJ; Yi HA; Choi MS; Heo JH; Park KW; Kim KK; Choi SH
    Dement Geriatr Cogn Disord; 2012; 34(3-4):167-73. PubMed ID: 23051684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment.
    Devanand DP; Pelton GH; Zamora D; Liu X; Tabert MH; Goodkind M; Scarmeas N; Braun I; Stern Y; Mayeux R
    Arch Neurol; 2005 Jun; 62(6):975-80. PubMed ID: 15956169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between the efficacy of rivastigmine and apolipoprotein E (epsilon4) in patients with mild to moderately severe Alzheimer disease.
    Blesa R; Aguilar M; Casanova JP; Boada M; Martínez S; Alom J; de la Hoz CH; Sancho J; Fernández O; Gil-Neciga E; Massó JF
    Alzheimer Dis Assoc Disord; 2006; 20(4):248-54. PubMed ID: 17132969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.